Loading clinical trials...
Loading clinical trials...
A Dose-Escalation Treatment, Phase 1, Investigator- and Participant-Blind, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3457263 in Combination With Tirzepatide in Overweight or Obese Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants. The study will also evaluate how much of LY3457263 gets into the blood stream and how long it takes the body to remove it in overweight or obese participants. The study will last up to approximately 11 weeks.
Age
20 - 70 years
Sex
ALL
Healthy Volunteers
Yes
LabCorp CRU, Inc.
Daytona Beach, Florida, United States
Start Date
November 11, 2022
Primary Completion Date
June 8, 2023
Completion Date
June 8, 2023
Last Updated
July 18, 2023
38
ACTUAL participants
LY3457263
DRUG
Tirzepatide
DRUG
Placebo
DRUG
Lead Sponsor
Eli Lilly and Company
NCT07472881
NCT01143454
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions